CHROMADEX CORP (CDXC)

ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

In today's session, these stocks are experiencing unusual volume.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024

ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+

CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024

CDXC stock results show that ChromaDex missed on revenue for the second quarter of 2024.

CDXC Stock Earnings: ChromaDex Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ChromaDex (NASDAQ:CDXC) just reported results for the second quarter of 2024.Th...

ChromaDex Corporation Reports Second Quarter 2024 Financial Results

ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

ChromaDex to Join Russell 2000® Index

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024

CDXC stock results show that ChromaDex beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ChromaDex (NASDAQ:CDXC) just reported results for the first quarter of 2024.Chr...